CYP1B1 polymorphisms and k-ras mutations in patients with pancreatic ductal adenocarcinoma.
The frequency of CYP1B1 polymorphisms in pancreatic cancer has never been reported. There is also no evidence on the relationship between CYP1B1 variants and mutations in ras genes (K-, H- or N-ras) in any human neoplasm. We analyzed the following CYP1B1 polymorphisms in 129 incident cases of pancreatic ductal adenocarcinoma (PDA): the m1 allele (Val to Leu at codon 432) and the m2 allele (Asn to Ser at codon 453). The calculated frequencies for the m1 Val and m2 Asn alleles were 0.45 and 0.68, respectively. CYP1B1 genotypes were out of Hardy-Weinberg equilibrium; this was largely due to K-ras mutated PDA cases. The Val/Val genotype was over five times more frequent in PDA cases with a K-ras mutation than in wild-type cases (OR = 5.25; P = 0.121). In PDA, polymorphisms in CYP1B1 might be related with K-ras activation pathways.
Crous-Bou
Marta
M
Institut Municipal d'Investigació Mèdica (IMIM), CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain.
De Vivo
Immaculata
I
Porta
Miquel
M
Pumarega
José A
JA
López
Tomàs
T
Alguacil
Joan
J
Morales
Eva
E
Malats
Núria
N
Rifà
Juli
J
Hunter
David J
DJ
Real
Francisco X
FX
D000230:Adenocarcinoma / Q000235:genetics*; D000483:Alleles; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065633:Cytochrome P-450 CYP1B1; D005260:Female; D011905:Genes, ras; D005838:Genotype; D006801:Humans; D016015:Logistic Models; D008297:Male; D009154:Mutation / Q000235:genetics; D010183:Pancreatic Ducts / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000235:genetics*; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D013030:Spain
D001189:Aryl Hydrocarbon Hydroxylases; C585496:CYP1B1 protein, human; D065633:Cytochrome P-450 CYP1B1